David Greenwald
Dave Greenwald, Ph.D., serves on the Board of Directors at Jaguar Gene Therapy, Axovia Therapeutics and Apertura Gene Therapy and is Vice President of Business Development on the therapeutics investment team at Deerfield Management. Since joining Deerfield in 2018, Dr. Greenwald has been responsible for searching for new investment opportunities, supporting business development of private portfolio companies, and providing his expertise to Deerfield’s research collaborations and venture creation efforts. Prior to joining Deerfield, Greenwald was the Director of Business Development at Johns Hopkins Technology Ventures and a co-founder and Chief Executive Officer of Relay Technology Management, Inc. Greenwald earned his B.S. in Cellular Biology & Molecular Genetics from University of Maryland, College Park and his Ph.D. in Genetics from Tufts University School of Medicine, where his doctoral thesis focused on gene therapy strategies to treat retinal degenerative diseases.
-
MedCity Influencers, BioPharma
Gene therapy is saving lives; There are still key challenges to realize its full potential
Gene therapy can offer hope to patients with previously untreatable diseases, but there’s more work to be done to improve both the safety and efficacy of this therapeutic modality.
Promoted
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
